Last reviewed · How we verify
Midodrine + pyridostigmine
Midodrine and pyridostigmine together increase blood pressure and improve symptoms of orthostatic hypotension by enhancing sympathetic activation and acetylcholine availability.
Midodrine and pyridostigmine together increase blood pressure and improve symptoms of orthostatic hypotension by enhancing sympathetic activation and acetylcholine availability. Used for Orthostatic hypotension.
At a glance
| Generic name | Midodrine + pyridostigmine |
|---|---|
| Also known as | Combination |
| Sponsor | Seoul National University Hospital |
| Drug class | Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination |
| Target | Alpha-1 adrenergic receptor; acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Midodrine is an alpha-1 adrenergic agonist that directly increases peripheral vasoconstriction and blood pressure. Pyridostigmine is an acetylcholinesterase inhibitor that enhances parasympathetic tone and can improve blood pressure regulation through central and peripheral mechanisms. The combination is used to address orthostatic hypotension through complementary pathways.
Approved indications
- Orthostatic hypotension
Common side effects
- Supine hypertension
- Piloerection
- Urinary retention
- Headache
- Tremor
Key clinical trials
- The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury (PHASE2)
- Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study (PHASE4)
- Treatment of Orthostatic Hypotension in Autonomic Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midodrine + pyridostigmine CI brief — competitive landscape report
- Midodrine + pyridostigmine updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI